Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy-Reference-Cited by-同舟云学术

Improving the safety of CAR‐T‐cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B‐cell lymphoma undergoing CAR‐T‐cell therapy

Published:2024-01-10 Issue:4 Volume:99 Page:662-678
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Qian Hu¹²^ORCID,Yang Xingcheng¹²^ORCID,Zhang Tingting³⁴⁵,Zou Ping⁶,Zhang Yicheng¹²,Tian Weiwei⁴⁵,Mao Zekai¹²^ORCID,Wei Jia¹²⁴⁵^ORCID

Affiliation:

1. Department of Hematology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China

2. Immunotherapy Research Center for Hematologic Diseases of Hubei Province Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China

3. Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital Third Hospital of Shanxi Medical University Taiyuan China

4. Department of Hematology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital Third Hospital of Shanxi Medical University Taiyuan China

5. Sino‐German Joint Oncological Research Laboratory Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Taiyuan China

6. Department of Hematology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China

Abstract

AbstractChimeric antigen receptor (CAR) T‐cell therapy, an innovative immunotherapeutic against relapsed/refractory B‐cell lymphoma, faces challenges due to frequent viral infections. Despite this, a comprehensive review addressing risk assessment, surveillance, and treatment management is notably absent. This review elucidates immune response compromises during viral infections in CAR‐T recipients, collates susceptibility risk factors, and deliberates on preventive strategies. In the post‐pandemic era, marked by the Omicron variant, new and severe threats to CAR‐T therapy emerge, necessitating exploration of preventive and treatment measures for COVID‐19. Overall, the review provides recommendations for viral infection prophylaxis and management, enhancing CAR‐T product safety and recipient survival.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27198

Reference141 articles.

1. CAR T cell toxicity: current management and future directions;Yanez L;Hema,2019

2. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

3. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions

4. CAR T-cell therapies in China: rapid evolution and a bright future

5. Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy;Frontiers in Oncology;2024-06-19

2. Endoplasmic reticulum stress and therapeutic strategies in metabolic, neurodegenerative diseases and cancer;Molecular Medicine;2024-03-20